Eam Global Investors LLC Revance Therapeutics, Inc. Transaction History

Eam Global Investors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $906,788 - $1.8 Million	63,279 New	63,279 $1.71 Million
Q3 2020 Nov 13, 2020	SELL	$23.23 - $34.3 $941,767 - $1.39 Million	-40,541 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$12.6 - $26.55 $874,414 - $1.84 Million	-69,398 Reduced 63.12%	40,541 $990,000
Q1 2020 May 13, 2020	SELL	$12.46 - $27.81 $330,239 - $737,076	-26,504 Reduced 19.42%	109,939 $1.63 Million
Q4 2019 Feb 10, 2020	BUY	$11.66 - $20.15 $1.59 Million - $2.75 Million	136,443 New	136,443 $2.21 Million
Q2 2018 Aug 03, 2018	SELL	$27.45 - $33.35 $1.23 Million - $1.5 Million	-44,898 Closed	0 $0
Q4 2017 Jun 04, 2018	BUY	$24.55 - $36.3 $1.1 Million - $1.63 Million	44,898	44,898 $1.61 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Eam Global Investors LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Global Investors LLC with notifications on news.